US Market Wrap
Wednesday November 29, 2023
US stocks finished flat, bond yields fell
S&P -0.1%, Nasdaq -0.1%, Russell +0.6%
Best: Real Estate +0.7%, Financials +0.5%
Worst: Communications -1.1%, Energy -0.9%
US 10 year yield -0.06% at 4.26%
Crude Oil +1.9%, Gold +0.3%, Copper -0.4%
SPI futures closed the session +0.1%
Financial Markets Institute of Australia
Macquarie Bank Hires Teenager
Marcus Tuck
Head of Research
7.00 am 7 August 2020
The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?
Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.
To read the full report … Login Here
Investing Styles That Work
Marcus Tuck
Head of Research
7.00 am 7 August 2020
The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?
Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.
To read the full report … Login Here
Our Diploma versus Any Degree
Marcus Tuck
Head of Research
7.00 am 7 August 2020
The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?
Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.
To read the full report … Login Here
How To Get Your Dream Job
Marcus Tuck
Head of Research
7.00 am 7 August 2020
The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?
Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.